Drugs

Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs

1 month ago   |   By Xconomy

The dog days of summer are here and IPO activity has slowed, but that hasn't stopped some biotech companies from securing a place in the line leading to Wall Street. Late Friday, SpringWorks Therapeutics and Satsuma Pharmaceuticals filed paperwork to go public. SpringWorks spun out of Pfizer nearly two years ago, aiming to acquire drug candidates that stalled within or were shelved by larger pharmaceutical companies. The Stamford, CT, company set its sights on rare diseases and cancer. To start, it secured the rights to four compounds that no longer fit Pfizer's strategy. The most advanced...
Read more ...

 


Search by Tags

   Drugs      Drug      Therapeutics      Pharmaceutical      Biotech      BioTech      Rare Diseases      Pharmaceuticals      Cancer      National blog main      New York      New York blog main      New York top stories      Raleigh-Durham blog main      Raleigh-Durham top stories      San Francisco blog main      San Francisco top stories      Acute migrane      Bain Capital      Bausch Health      Breast Cancer      Clinical trials      Desmoid tumor      Dihydroergotamine      Dihydroergotamine mesylate      Generic drug      GlaxoSmithKline      Impel NeuroPharma      Life Sciences      Medical Device      Migraine      Multiple Myeloma      National Organization for Rare Disorders      Nirogacestat      Orbimed      RA Capital      Rare disease drugs      Satsuma Pharmaceuticals      Shin Nippon Biomedical Laboratories      SpringWorks Therapeutics      TPG Biotech  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Why Menlo Ventures Backed Its First Construction Tech Firm

Why Menlo Ventures Backed Its First Construction Tech Firm

Fieldwire , whose mobile app helps builders and construction crews coordinate their work, announced today it has lined up a total of $33.5 million across two newly disclosed... Read more ...

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

HMS's $36M Deal to Buy VitreosHealth Combines Complementary Firms

One Texas-based healthcare software business has acquired another in an all-cash deal worth $36.5 million, the companies announced late Monday. Irving, TX-based HMS Holdings... Read more ...

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

ESnet a Key Partner on Project to Build Novel Network Research Infrastructure

Anticipated FABRIC topology at the end of construction. The National Science Foundation is funding a collaborative effort to create a nationwide research infrastructure that... Read more ...

Automated Trucking Company TuSimple Adds $120M More From Investors

Automated Trucking Company TuSimple Adds $120M More From Investors

UPS, the global package delivery giant, took a minority stake this summer in TuSimple, a self-driving trucking company, but didn't reveal financial details. On Tuesday, the San... Read more ...

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Inks Novartis Deal for Another Compromised-Immune System Drug

Amplyx Pharmaceuticals, which is testing a new type of drug against life-threatening infections acquired by patients with compromised immune systems, has acquired the rights to... Read more ...

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Lundbeck Paying Nearly $2B for Alder to Follow Migraine Rivals to Market

Denmark's neuroscience-focused pharma firm Lundbeck has agreed to pay $1.95 billion to acquire Seattle-based Alder BioPharmaceuticals to boost its late-stage pipeline and... Read more ...

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

KATRIN Cuts the Mass Estimate for the Elusive Neutrino in Half

A diagram of the layout and major features of the KATRIN experimental facility at the Karlsruhe Institute of Technology. (Credit: Karlsruhe Institute of Technology) Note: This... Read more ...

101601 CTRI CCR Operations Manager

CLINICAL TRANSLA RESEARCH INST Salary commensurate with qualifications and experienceFiling Deadline: Tue 10/1/2019... Read more ...

101667 Sr. Licensed Vocational Nurse

CLINICAL TRANSLA RESEARCH INST Salary commensurate with qualifications and experienceFiling Deadline: Tue 9/24/2019... Read more ...

Improvement of Fab expression by screening combinatorial synonymous signal...

Antibody fragments can be expressed in Escherichia coli, where they are commonly directed to the periplasm via Sec pathway to enable disulphide bridge formations and correct... Read more ...